Deltec Asset Management LLC Grows Stake in Boston Scientific Corporation $BSX

Deltec Asset Management LLC lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 51.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 42,800 shares of the medical equipment provider’s stock after purchasing an additional 14,500 shares during the period. Deltec Asset Management LLC’s holdings in Boston Scientific were worth $4,179,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Riverwater Partners LLC increased its position in Boston Scientific by 3.3% in the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after buying an additional 98 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management grew its stake in shares of Boston Scientific by 3.8% during the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock worth $291,000 after acquiring an additional 99 shares during the period. Crown Wealth Group LLC increased its holdings in Boston Scientific by 4.7% in the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after acquiring an additional 100 shares during the last quarter. IVC Wealth Advisors LLC increased its holdings in Boston Scientific by 4.9% in the 2nd quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock worth $236,000 after acquiring an additional 102 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC raised its stake in Boston Scientific by 3.9% in the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after acquiring an additional 103 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 93,095 shares of company stock worth $9,305,450. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 0.7%

Boston Scientific stock opened at $97.68 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The stock has a market cap of $144.80 billion, a P/E ratio of 52.23, a PEG ratio of 1.73 and a beta of 0.67. The firm’s fifty day moving average price is $97.58 and its 200-day moving average price is $100.76.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the previous year, the business earned $0.63 earnings per share. The firm’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on BSX. Cowen reiterated a “buy” rating on shares of Boston Scientific in a research report on Thursday, December 11th. Barclays lifted their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, December 20th. Evercore ISI set a $112.00 price target on Boston Scientific in a report on Monday, January 5th. Finally, Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $125.21.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.